You can buy or sell SNDX and other stocks, options, ETFs, and crypto commission-free!
Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include candidate and entinostat. Read More The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.
52 Week High
52 Week Low
Seeking AlphaMar 14
Syndax Pharmaceuticals (SNDX) Investor Presentation - Slideshow
The following slide deck was published by Syndax Pharmaceuticals, Inc. in conjunction with this event. 1 28 Click to enlarge Notes:...
Seeking AlphaMar 8
Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q4 2018 Results - Earnings Call Transcript
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2018 Results Earnings Conference Call March 7, 2019 4:30 PM ET Company Participants Melissa Forst - Argot Partners, VP Briggs Morrison - CEO Richard Shea - CFO & Treasurer Michael Metzger - President & COO Michael Meyers - Chief Medical Officer & Senior VP Peter Ordentlich - Co-Founder & Chief Scientific Officer Conference Call Participants Christopher Marai - Nomura Instinet Chris Shibutani - Cowen Jake Colby - BTIG David Lebowitz - Morgan Stanley ...
PR NewswireMar 7
Syndax Pharmaceuticals Reports Fourth Quarter 2018 Financial Results and Provides Clinical and Business Update
WALTHAM, Mass., March 7, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the fourth quarter ended December 31, 2018. In addition, the Company provided a clinical and business update. As of December 31, 2018, Syndax had $80.9 million in cash, cash equivalents and short-term investments. "We expect the coming months to b...
-$0.67 per share
-$0.70 per share